Stock Groups

U.S. judge rejects Shkreli’s request to delay $64.6 million payment pending appeal -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO. Martin Shkreli is a former drug company executive and arrives at U.S. District Court on the third day jury deliberations for his Securities Fraud trial. The proceedings took place in Brooklyn borough, New York City. August 2, 2017. REUTERS/Amr Alfiky/File photo

WASHINGTON (Reuters] – Martin Shkreli, a federal judge rejected his request for a delay of $64.6 million in payment. Shkreli is currently appealing to the Federal Trade Commission regarding whether he breached antitrust law and sharply increased the price of a life-saving medication.

U.S. District Judge Denise Cote of Manhattan had in January ruled for the FTC, seven states and Shkreli. He was accused of illegally pushing Daraprim’s price to $750 per tablet, from $17.50 in 2015, while keeping rivals off the market.

Shkreli is currently in prison and was barred by the judge from working in the pharmaceutical industry. Shkreli was also barred by another judge from being an officer or director in a publicly traded firm.

Disclaimer: Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]